doi.org/10.1093/annonc/mdz394.029

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

,

,

..., Bruno Sangro

Annals of Oncology65.40

Volume: 30, Pages: v874 - v875

Published: Oct 1, 2019

Paper Fields

Paper Details

Title

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

DOI

doi.org/10.1093/annonc/mdz394.029

Published Date

Oct 1, 2019

Journal

Annals of Oncology

Volume

30

Pages

v874 - v875

Notes

History